TransMedics
TMDX
85.25
-8.77
-9.33%
TransMedics
US · TMDX
#2536 by market cap
Listed 2019
85.25
-8.77
-9.33%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
- Total institutional ownership rose 1.3 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 103.65% +1.32pp
- Institutions
- 451 +5
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund86.11%
Hedge Fund7.21%
Public Company6.07%
Individual/Insider3.18%
Private Company2.12%
Government Pension Fund1.15%
Insurance Company0.43%
Endowment Fund0.23%
Family Office/Trust0.19%
Top holders as of 2026-09-30
BlackRock
15.81% · 5.49M sh
FMR
14.88% · 5.17M sh
Vanguard Portfolio Management, LLC
5.25% · 1.83M sh
Vanguard Capital Management, LLC
4.31% · 1.50M sh
State Street Global Advisors
4.10% · 1.43M sh
Macquarie Investment Management Business Trust
2.62% · 910.50K sh
Geode Capital Management, LLC
2.56% · 888.69K sh
Barrow, Hanley, Mewhinney & Strauss, LLC
2.41% · 837.53K sh
UBS Asset Management
2.33% · 808.16K sh
Emerald Advisers, LLC
2.31% · 803.95K sh
Hood River Capital Management LLC
2.17% · 751.13K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| Waleed Hassanein | Chief Executive Officer | 1.62% |
| Edwin Kania | Independent Director | 0.88% |
| James Tobin | Independent Chairperson | 0.46% |
| Tamer Khayal | Senior Vice President of International | 0.04% |
| Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | 0.04% |
| Thomas Gunderson | Independent Director | 0.04% |
| David Weill | Independent Director | 0.04% |
| Anil Ranganath | Former Advisor | 0.01% |
| Merilee Raines | Independent Director | 0.01% |
| Gerardo Hernandez | Former Chief Financial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-08 | James Tobin | Independent Chairperson | Open Market Disposition | -4,059 | $93.96–94.98 |
| 2026-10-27 | Fernando Araujo | Chief Financial Officer & Treasurer | Other Acquisition | +22,969 | -- |
| 2026-10-27 | Fernando Araujo | Chief Financial Officer & Treasurer | Other Derivative Acquisition | +34,419 | $66.90 |
| 2026-09-10 | David Weill | Independent Director | Open Market Acquisition | +1,336 | $81.63 |
| 2026-08-16 | James Tobin | Independent Chairperson | Other Disposition | -18,000 | -- |
| 2026-07-09 | Waleed Hassanein | Chief Executive Officer | Other Acquisition | +49,669 | -- |
| 2026-07-09 | Waleed Hassanein | Chief Executive Officer | Other Derivative Acquisition | +112,984 | $71.23 |
| 2026-07-09 | Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | Other Acquisition | +11,727 | -- |
| 2026-07-09 | Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | Other Derivative Acquisition | +17,784 | $71.23 |
| 2026-07-09 | Gerardo Hernandez | Former Chief Financial Officer | Other Acquisition | +17,246 | -- |
| 2026-07-09 | Gerardo Hernandez | Former Chief Financial Officer | Other Derivative Acquisition | +26,153 | $71.23 |
| 2026-06-14 | Thomas Gunderson | Independent Director | Derivative Exercise and Sale | -9,624 | $2.21–75.06 |
| 2026-06-14 | Thomas Gunderson | Independent Director | Derivative Exercise and Retained | +9,661 | $2.21 |
| 2026-05-19 | Edwin Kania | Independent Director | Other Acquisition | +2,922 | -- |
| 2026-05-19 | Merilee Raines | Independent Director | Other Acquisition | +2,922 | -- |
| 2026-05-19 | James Tobin | Independent Chairperson | Other Acquisition | +2,922 | -- |
| 2026-05-19 | Edward Basile | Independent Director | Other Acquisition | +2,922 | -- |
| 2026-05-19 | Stephanie Lovell | Independent Director | Other Acquisition | +2,922 | -- |
| 2026-05-19 | Thomas Gunderson | Independent Director | Other Acquisition | +2,922 | -- |
| 2026-05-19 | David Weill | Independent Director | Other Acquisition | +2,922 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
TransMedics discussion 0 comments